Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab in recent-onset type 1 diabetes mellitus
2009-011606-41Phase 3Completed
- Sponsor
- MacroGenics
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of teplizumab in diabetes mellitus type 1 (T1D) (4 arms), sponsored by MacroGenics. Primary endpoint: Composite insulin use and glycemic control responder rate at Day 364. Started Jul 2009; status: completed.
02
Drugs
teplizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2009-011606-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011606-41.